Dr. Daniel Von Hoff Joins INSYS Therapeutics/NeoPharm as Chief Development Officer
(BUSINESS WIRE)--INSYS Therapeutics/NeoPharm (Other OTC: NEOL.PK) announces the inclusion of Daniel D. Von Hoff, M.D., F.A.C.P. to their management team as Chief Development Officer. Dr. Von Hoff also currently serves as Physician in Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for Scottsdale Healthcare. He holds an appointment as Clinical Professor of Medicine, University of Arizona, College of Medicine.